We hypothesize that the LIF/LIFR axis could be involved in the progression of IBC, and the genetic or pharmacological inhibition of LIFR could be a therapeutic strategy to slow IBC progression. This evidence concerns the gene LIFR and inflammatory breast carcinoma.